ADC Antibody Drug Conjugate
Antibody–Drug Conjugates (ADCs) are an advanced class of cancer therapeutics that combine the precision of targeted therapy with the potency of chemotherapy. They are designed to selectively deliver powerful anti-cancer drugs directly to tumor cells while limiting damage to healthy tissue, making them a key innovation in modern oncology.
Deliver poison selectively inside cancer cells
An ADC consists of three main components: a monoclonal antibody, a cytotoxic payload, and a
linker that connects them. The antibody recognize a specific antigen expressed on cancer cells like a guided delivery system. Once bound, the ADC is internalized into the cancer cell.
A major advantage of ADCs is their ability to use drugs that would be too toxic if given systemically. ADCs have already shown success in treating several cancers, including breast, lymphomas, andmany more are in development. Their modular design allows researchers to adapt them for different cancer types by swapping out the antibody, linker, or payload.
Overall, ADCs represent a powerful shift toward more precise and effective cancer treatment.
By combining targeted delivery with high potency, they offer a promising path forward in the
fight against cancer.
